FDA Approves Truvada for Use in Adolescents

The US Food and Drug Administration (FDA) has approved Gilead's once-daily oral Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) to reduce the risk of sexually acquired HIV-1 in at-risk adolescents weighing at least 35kg when used in combination with safe sex practices. When taken consistently, pre-exposure prophylaxis, such as Truvada, can reduce the risk of HIV infection by 92%. Continue reading

News: South Korea Approve PrEP

  Health Ministry Approves HIV Prevention Drug, but High Price Remains an Obstacle    Continue reading